Arul Vijaya Vani S, Ananthanarayanan P H, Kadambari D, Harichandrakumar K T, Niranjjan R, Nandeesha H
Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry-6, India.
Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry-6, India.
Clin Chim Acta. 2016 Aug 1;459:53-56. doi: 10.1016/j.cca.2016.05.020. Epub 2016 May 21.
Vitamin D deficiency (<10ng/mL) and insufficiency (10-30ng/mL) may contribute to musculoskeletal symptoms observed in patients taking letrozole. This study was undertaken to assess the vitamin D status in breast cancer patients who received letrozole for >2months and to see the effects of vitamin D3 and calcium supplementation on them.
Eighty-two breast cancer patients were included. Baseline serum 25-hydroxy vitamin D concentrations were assayed and standard questionnaire was completed. They were given vitamin D3 and calcium supplementation (2000IU/1000 mg and 4000IU/1000mg) based on their baseline serum 25-hydroxy vitamin D concentration for 12weeks.
Baseline serum 25-hydroxy vitamin D concentrations showed that 13.4% of patients were deficient and 73.2% of patients were insufficient in 25-hydroxy vitamin D. There was an increase in the concentrations of calcium, phosphorus and decrease in the concentrations of parathyroid hormone, alkaline phosphatase as the concentration of serum 25-hydroxy vitamin D increases. Patients who received letrozole for a longer duration had a low concentration of serum 25 (OH) vitamin D. Vitamin D3 and calcium supplementation increased the concentrations of calcium, phosphorous and decreased the concentrations of parathyroid hormone and alkaline phosphatase. Patients who had low serum 25-hydroxy vitamin D concentrations had more musculoskeletal symptoms which was improved following supplementation (9.14 vs 8.10 p=0.000).
Vitamin D3 supplementation significantly improved serum 25-hydroxy vitamin D concentrations and decreased letrozole-induced arthralgia.
维生素D缺乏（<10ng/mL）和不足（10 - 30ng/mL）可能导致服用来曲唑的患者出现肌肉骨骼症状。本研究旨在评估接受来曲唑治疗超过2个月的乳腺癌患者的维生素D状态，并观察维生素D3和钙补充剂对他们的影响。
纳入82例乳腺癌患者。测定基线血清25 - 羟基维生素D浓度并完成标准问卷。根据他们的基线血清25 - 羟基维生素D浓度，给予他们维生素D3和钙补充剂（2000IU/1000mg和4000IU/1000mg），持续12周。
基线血清25 - 羟基维生素D浓度显示，13.4%的患者存在维生素D缺乏，73.2%的患者25 - 羟基维生素D不足。随着血清25 - 羟基维生素D浓度的增加，钙、磷浓度升高，甲状旁腺激素、碱性磷酸酶浓度降低。接受来曲唑治疗时间较长的患者血清25（OH）维生素D浓度较低。维生素D3和钙补充剂增加了钙、磷浓度，降低了甲状旁腺激素和碱性磷酸酶的浓度。血清25 - 羟基维生素D浓度低的患者有更多的肌肉骨骼症状，补充后症状得到改善（9.14对8.10，p = 0.000）。
补充维生素D3显著改善了血清25 - 羟基维生素D浓度，并减轻了来曲唑引起的关节痛。
Zotero 插件